Japan Clears Nine Drugs For Approval, But Only A New DPP-4 Is First Out The Gate
This article was originally published in PharmAsia News
Executive Summary
Despite MHLW's progress in cutting the drug lag, no drugs from a June 29 batch of approvals are first-to-market save for a DPP-4 from Mitsubishi Tanabe, which enters a crowded market.
You may also be interested in...
China's Simcere Beats Out Eisai In Iguratimod Approval For Rheumatoid Arthritis
SHANGHAI- China's State FDA cleared Simcere Pharmaceutical Group's new drug application for Iremod (iguratimod) for rheumatoid arthritis, in the world's first approval of the compound, Simcere announced Aug. 25
Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter
Co-promotion partner Takeda will focus sales activities on office-based gastroenterologists and primary care physicians, while Sucampo will target medical centers and the VA.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?